Ernexa Therapeutics Inc.
Ernexa Therapeutics Inc. (ERNA) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
erna · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Ernexa Therapeutics Inc. (ERNA) measures how much investors pay for each dollar of the company's trailing earnings. ERNA's current PE ratio of N/A is calculated by dividing its stock price of $7.39 by its TTM earnings per share of -$14.38.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2015 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Ernexa Therapeutics Inc.You ERNA | $2M | N/A | — | -$14.38 |
 Adaptimmune Therapeutics plc ADAP | $75M | N/A | — | -$0.28 |
 Aethlon Medical, Inc. AEMD | $2M | N/A | — | -$85.77 |
 AEON Biopharma, Inc. AEON | $9M | N/A | — | -$3.95 |
 Dogwood Therapeutics, Inc. DWTX | $3M | N/A | — | -$4.17 |
 Lunai Bioworks Inc. LNAI | $11M | N/A | — | -$86.27 |
 Moleculin Biotech, Inc. MBRX | $3M | N/A | — | -$2.83 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-55.83 | — | |
2024-12-31 FY2024 | — | $-39.21 | — | |
2023-12-31 FY2023 | — | $-101.94 | — | |
2022-12-31 FY2022 | — | $-201.40 | — | |
2021-12-31 FY2021 | — | $-1415.07 | — | |
2020-12-31 FY2020 | 195.61x | $171.77 | — | |
2019-12-31 FY2019 | — | $-712.00 | — | |
2018-12-31 FY2018 | — | $-96.35 | — | |
2017-12-31 FY2017 | — | $-441.03 | — | |
2016-12-31 FY2016 | — | $-1536.00 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Ernexa Therapeutics Inc. (ERNA) measures how much investors pay for each dollar of the company's trailing earnings. ERNA's current PE ratio of N/A is calculated by dividing its stock price of $7.39 by its TTM earnings per share of -$14.38.
Frequently asked questions
ERNA pe ratio · 6 questionsERNA's current PE ratio is N/A as of 2026-06-09, based on a stock price of $7.39 and TTM EPS of -$14.38. Data sourced from Financial Modeling Prep via ERNA's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Ernexa Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09